Latest Aggregates News

Page 16 of 17
Pinnacle Investment Management Group Limited has reported a remarkable 150.5% increase in net profit for the half year ended 31 December 2024, alongside a 16.7% rise in revenues and a healthy interim dividend announcement.
Claire Turing
Claire Turing
4 Feb 2025
Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.
Ada Torres
Ada Torres
3 Feb 2025
Dateline Resources has released a promising scoping study for its Colosseum Gold Project in California, projecting robust gold production and revenue. The company is now progressing to a bankable feasibility study while exploring innovative uses for mining waste in the concrete industry.
Maxwell Dee
Maxwell Dee
3 Feb 2025
X2M Connect reported a 51% revenue drop in Q2 FY25 as it shifts from hardware to SaaS, yet improved margins and EBITDA signal progress. Strategic partnerships in the Middle East and Taiwan offer promising growth avenues.
Sophie Babbage
Sophie Babbage
31 Jan 2025
AustChina Holdings Limited reports steady progress in its Blackall Coal Project and copper investments, while exploring innovative coal processing technologies and assessing new mineral resource opportunities.
Maxwell Dee
Maxwell Dee
31 Jan 2025
Pacific Current Group reports a 6.1% increase in total Funds Under Management to A$30 billion as of December 31, 2024, despite a decline in USD-denominated assets and exits from two boutique managers.
Claire Turing
Claire Turing
31 Jan 2025
Alterity Therapeutics has reported positive Phase 2 results for ATH434, showing significant slowing of Multiple System Atrophy progression and a favorable safety profile. The trial demonstrated clinical benefits alongside reductions in brain iron accumulation, a key disease driver.
Ada Torres
Ada Torres
30 Jan 2025
Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.
Ada Torres
Ada Torres
30 Jan 2025
Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.
Ada Torres
Ada Torres
29 Jan 2025
RemSense Technologies delivered a cashflow positive Q2 FY2025, driven by a 78% surge in customer receipts and successful execution of major global contracts. The company’s virtualplant platform continues to gain traction across mining, oil and gas, and new industrial sectors.
Sophie Babbage
Sophie Babbage
29 Jan 2025
Singular Health has secured a pivotal MoU with Miami-based Provider Network Solutions and raised $3.7 million to propel its 3Dicom software towards a US commercial pilot, supported by the appointment of esteemed radiologist Dr. Ronny Low.
Victor Sage
Victor Sage
28 Jan 2025
Astral Resources has reported its most significant diamond drilling results to date at the Theia Deposit within the Mandilla Gold Project, with drill-hole MDRCD918 delivering an exceptional 1,079 gram-metres of gold mineralisation. This breakthrough is expected to underpin an upgrade of the resource classification ahead of a Mineral Resource Estimate update scheduled for March 2025.
Maxwell Dee
Maxwell Dee
28 Jan 2025